Short Interest in Protara Therapeutics, Inc. (NASDAQ:TARA) Expands By 79.1%

Protara Therapeutics, Inc. (NASDAQ:TARA) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 5,410,000 shares, a growth of 79.1% from the November 30th total of 3,020,000 shares. Based on an average trading volume of 2,200,000 shares, the short-interest ratio is currently 2.5 days.

Wall Street Analyst Weigh In

Several analysts have commented on TARA shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th. Guggenheim reaffirmed a “buy” rating and issued a $20.00 target price on shares of Protara Therapeutics in a report on Friday, December 6th.

Institutional Investors Weigh In On Protara Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new position in Protara Therapeutics during the second quarter valued at $1,082,000. CVI Holdings LLC bought a new stake in Protara Therapeutics during the 2nd quarter valued at about $630,000. Oppenheimer & Co. Inc. boosted its position in Protara Therapeutics by 40.8% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 179,125 shares of the company’s stock valued at $328,000 after buying an additional 51,944 shares during the period. Geode Capital Management LLC grew its stake in Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after acquiring an additional 29,514 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Protara Therapeutics by 77.8% in the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock valued at $313,000 after purchasing an additional 65,800 shares during the last quarter. 38.13% of the stock is owned by institutional investors.

Protara Therapeutics Trading Up 0.2 %

Shares of TARA stock traded up $0.01 on Friday, reaching $5.51. The company’s stock had a trading volume of 347,904 shares, compared to its average volume of 741,171. The stock’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $2.59. Protara Therapeutics has a 1 year low of $1.60 and a 1 year high of $10.48. The company has a market capitalization of $113.67 million, a price-to-earnings ratio of -1.95 and a beta of 1.78.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, hitting analysts’ consensus estimates of ($0.50). Equities research analysts forecast that Protara Therapeutics will post -2.99 earnings per share for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.